Oncology Communications
ISSN: pending (Online)
Email: [email protected]
Submit Manuscript
Edit a Special Issue
TY - JOUR AU - Jiang, Wenmei AU - Huang, Xiancong AU - Tian, Jiayuan AU - Wu, Yimin AU - Zhao, Jiazheng AU - Luo, Taobo AU - Zeng, Jian AU - Cai, Shunv AU - Wu, Leilei PY - 2026 DA - 2026/01/29 TI - Revisiting The Dual Role of Radiotherapy in EGFR-mutant NSCLC: Implications for Therapeutic Combination Strategies JO - Oncology Communications T2 - Oncology Communications JF - Oncology Communications VL - 1 IS - 1 SP - 5 EP - 7 DO - 10.62762/OC.2025.306213 UR - https://www.icck.org/article/abs/OC.2025.306213 KW - non-small cell lung cancer KW - EGFR KW - radiotherapy KW - combination strategies KW - EGFR-TKI AB - The article by Piffkó A et al. elucidates the double-edged sword role of radiotherapy in cancer treatment. Radiotherapy stimulates tumor cells to secrete amphiregulin (AREG), which in turn activates EGFR$^+$ tumor-associated mononuclear phagocytes (MNPs). This activation feeds back into the EGFR signaling pathway, impairing the anti-tumor functions of MNPs. Moreover, AREG upregulates the expression of the immune checkpoint protein CD47 in tumor cells, thereby enabling them to evade immune-mediated phagocytosis. These insights hold important implications for clinical trial design and for optimizing therapeutic strategies. SN - pending PB - Institute of Central Computation and Knowledge LA - English ER -
@article{Jiang2026Revisiting,
author = {Wenmei Jiang and Xiancong Huang and Jiayuan Tian and Yimin Wu and Jiazheng Zhao and Taobo Luo and Jian Zeng and Shunv Cai and Leilei Wu},
title = {Revisiting The Dual Role of Radiotherapy in EGFR-mutant NSCLC: Implications for Therapeutic Combination Strategies},
journal = {Oncology Communications},
year = {2026},
volume = {1},
number = {1},
pages = {5-7},
doi = {10.62762/OC.2025.306213},
url = {https://www.icck.org/article/abs/OC.2025.306213},
abstract = {The article by Piffkó A et al. elucidates the double-edged sword role of radiotherapy in cancer treatment. Radiotherapy stimulates tumor cells to secrete amphiregulin (AREG), which in turn activates EGFR\$^+\$ tumor-associated mononuclear phagocytes (MNPs). This activation feeds back into the EGFR signaling pathway, impairing the anti-tumor functions of MNPs. Moreover, AREG upregulates the expression of the immune checkpoint protein CD47 in tumor cells, thereby enabling them to evade immune-mediated phagocytosis. These insights hold important implications for clinical trial design and for optimizing therapeutic strategies.},
keywords = {non-small cell lung cancer, EGFR, radiotherapy, combination strategies, EGFR-TKI},
issn = {pending},
publisher = {Institute of Central Computation and Knowledge}
}
Copyright © 2026 by the Author(s). Published by Institute of Central Computation and Knowledge. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. 
Portico
All published articles are preserved here permanently:
https://www.portico.org/publishers/icck/